Barclays PLC Buys 193,046 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Barclays PLC increased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 356.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 247,280 shares of the company’s stock after acquiring an additional 193,046 shares during the quarter. Barclays PLC owned about 0.12% of Taysha Gene Therapies worth $513,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TSHA. Wellington Management Group LLP acquired a new stake in Taysha Gene Therapies in the third quarter worth $931,000. State Street Corp raised its stake in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after buying an additional 150,647 shares during the period. MetLife Investment Management LLC lifted its holdings in Taysha Gene Therapies by 81.9% during the third quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after acquiring an additional 34,243 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Taysha Gene Therapies by 7.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after acquiring an additional 33,123 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Taysha Gene Therapies in the third quarter valued at about $85,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on TSHA shares. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Up 6.9 %

Taysha Gene Therapies stock opened at $1.85 on Friday. The company has a fifty day simple moving average of $2.10 and a 200 day simple moving average of $2.18. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 1-year low of $1.19 and a 1-year high of $4.32. The company has a market cap of $379.14 million, a P/E ratio of 2.94 and a beta of 0.79.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.